Company* (Country; Symbol)

Product

Description

Indication

Status (Date)


AUTOIMMUNE

Centocor Inc. (unit of Johnson & Johnson)

Remicade

Infliximab; anti-TNF antibody

Fistulizing Crohn's disease

Partner Schering-Plough Corp. received approval to market pro- duct in Europe for sustaining clinical response (10/23)

Millennium Pharmaceuticals Inc. (MLNM)

MLN1202

Humanized monoclonal antibody designed to block MCP-1/CCR2 chemokine pathway

Rheumatoid arthritis

Company began a Phase II trial that will include about 30 patients; trial to be conducted in Europe and Australia (10/14)

ProMetic Life Sciences Inc. (Canada; TSE:PLI) and Arriva Pharmaceuticals Inc.*

rAAT topical gel

Recombinant alpha-1 antitrypsin

Atopic dermatitis

Companies' joint venture opened a Phase II proof-of-concept trial in Canada (10/9)

Revotar Biophar- maceuticals Inc.* (Germany; majority-owned subsidiary of Encysive Pharmaceuticals Inc.; ENCY)

Bimosiamose

Topical formulation of small-molecule selecting antagonist

Psoriasis and atopic dermatitis

Company started controlled Phase IIa trial in each indication (10/9)

CANCER

Aphton Corp. (APHT)

G17DT

Anti-gastrin targeted immunotherapy

Pancreatic cancer

Results of Phase III trial in 154 patients in Europe showed increased survival in advanced patients for monotherapy arm vs. placebo (10/30)

Eximias Pharmaceutical Corp.*

Thymitaq

Thymidylate synthase inhibitor

Hepatocellular carcinoma

Eximias gained orphan designation for the product in Europe (10/9)

TopoTarget Prolifix A/S* (Denmark)

PXD101

Histone deacetylase Inhibitor

Advanced cancers

TopoTarget started a Phase I trial in 24 to 36 patients at sites in the UK (10/13)

CARDIOVASCULAR

Endovasc Inc. (OTC BB:EVSC)

Liprostin

Liposome formulation of prostaglandin E1

Critical limb ischemia and intermittent claudication

Endovasc got approval in Republic of Georgia to begin clinical trials; other sites are in Brazil, Mexico and Eastern Europe (10/8)

CENTRAL NERVOUS SYSTEM

Alkermes Inc. (ALKS)

Risperdal Consta

Long-acting injectable form of risperidone

Schizophrenia

Alkermes partner Janssen-Cilag SA gained approval in France (10/9)

Cephalon Inc. (CEPH)

Vigil; Provigil

Modafinil tablets

Excessive daytime

sleepiness

Cephalon gained approval in Ger-

many and Ireland (10/9)

Debiopharm SA*

(Switzerland)

ZT-1

Cholinesterase inhibitor

Alzheimer's

disease

Company said it would start a Phase

II trial in Europe in 180 patients with

mild to moderate AD (10/20)

INFECTION

Gilead Sciences Inc. (GILD)

Emtriva (FDA-approved)

Emtricitabine; nucleoside reverse transcriptase inhibitor

HIV

The European Union granted marketing approval in all 15 member states of the EU (10/28)

ID Biomedical Corp.* (Canada; IDBE)

FluINsure

Trivalent influenza vaccine for intranasal administration

Influenza

Company received approval in Canada for field trial in 1,320 healthy adults (10/16)

Ipsat Therapies Oy* (Finland)

P1A

Oral formulation designed to inactivate betalactam antibiotics

Antibiotic-induced problems

Company presented Phase I data showing successful removal of harmful antibiotic residue (10/13)

MedImmune Inc. (MEDI) and Abbott Laboratories

Synagis (FDA-approved)

Palivizumab; humanized monoclonal antibody

Congenital heart disease

Abbott gained approval in Europe to market drug for infants born with hemodynamically significant congenital heart disease (10/30)

MISCELLANEOUS

Abiogen Pharma SpA* (Italy)

OGP

Small sequence of osteogenic growth peptide

Chronic idiopathic myelofibrosis

EMEA granted orphan designation to the product (10/6)

Labopharm Inc.* (Canada)

Tramadol

Once-daily formulation of the analgesic

Pain associated with osteoarthritis

Data presented from European Phase III trial showed product provided equivalent efficacy to extended-release, twice-daily formulation (10/15)

Cangene Corp. (Canada; TSE:CNJ)

Leucotropin

GM-CSF protein

To enhance white blood cells in those with Hodgkin's disease or non- Hodgkin's lymphoma after stem cell transplantation

Cangene filed for approval in Canada (10/7)

Xcellentis (subsidiary of Innogentics NV; Belgium)

LymphoDerm

Agent in proprietary topical formulation

Hard-to-treat venous leg ulcers

Preliminary Phase II results in 195 patients studied in four countries showed a clear trend toward improvement vs. standard of care (10/28)


Notes:

* Privately held

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments